

One Million Euros Fundraised

Michel Goldman named Chairman of Scientific Advisory Board ,

two major strategic steps-forward for Effimune, the specialist in immune regulation

Boosted by this additional million euros and by the nomination of Professor Goldman as the President of its Scientific Advisory Board (SAB), Effimune pursues an ambitious yet realistic business strategy aimed at the regulation of the immune response in the treatment of autoimmune diseases, cancers and transplantation.

Nantes, the 10th March 2015

Renewed trust from existing investors

The funds raised, to the amount of € 1,070,700, came entirely from existing Effimune investors, who thus show their renewed trust in the company's development. These funds should enable Effimune to strengthen its capital base **and accelerate the development of its product pipeline**, including Effi7, an anti-IL-7 alpha receptor antibody.

The total funds raised by Effimune since its creation are about 5M€, all from the same investors: founders, family funds and business angels.

An expert in immunological therapeutic innovation as the head of our SAB



**Prof.
Michel Goldman**

Professor Michel Goldman is a key figure in the field of immunology. He brings to Effimune knowledge, skills and experience, fruit of a long and successful career. He has become an internationally recognized expert in Therapeutic Immunology with his scientific research producing more than 400 articles in peer-reviewed publications and has been the recipient of numerous academic awards.

Professor of Immunology at the "Université Libre de Bruxelles", from 2009 to 2014 Michel Goldman was the director of IMI (Innovative Medicines Initiative), the largest European public-private initiative aimed at speeding up the development of better and safer medicines and with a total budget of 2 billion euros.

Effimune

His mission as president of Effimune's SAB will be to support and guide the strategic development of the company in terms of science and medicine in accordance with health regulations and policies.

A clinician, researcher and entrepreneur, coordinator of Effimune's SAB

Professor Jean-Paul Soulillou, co-founder of the company, has made his mark on research in the field of immunology and transplantation as a clinician, researcher and entrepreneur.

First **President of Atlanpole Biotherapies cluster** from 2005 to 2008, he received **the 2012 Honor Award from Inserm**, for his lifetime achievement and his work on immune tolerance. He was at the origin of the development of a number original immunosuppression strategies including a monoclonal antibody introduced in the 90s and still used widely to promote engraftment. His mission as coordinator of our SAB is to be proactive in the strategic planning of meetings and the organization of the Council's work plan, and to be the link between the President, the SAB's scientific members and the management team of the company.



Prof.
Jean-Paul Soulillou

"Trust and credibility are at the heart of Effimune's development strategy. We welcome the renewed support from our investors who I thank for their support in facilitating the Effimune's development" says Maryvonne Hiance, President of Effimune. "The arrival of Professor Michel Goldman, such a well-respected personality, as the head of the Scientific Advisory Board is a very strong signal to the scientific world, but also to the industry and the financial sector on the capability of the Effimune technologies to regulate the immune system. Similarly, the ongoing support of Jean-Paul Soulillou and his appointment as the coordinator of the SAB shows the quality and the high standards of Effimune's scientific research," commented Bernard Vanhove, CEO of the company.

Pictures of Professors Michel Goldman and/or Jean-Paul Soulillou and Maryvonne Hiance are available on request from gilles.petitot@acorelis.com

About Effimune:

Located in Nantes (France), Effimune is a Biotechnology company specializing in the research and development of therapeutic molecules that regulate the immune system in the areas of transplantation, autoimmunity and cancer. Effimune stand-out product, FR104, shows remarkable efficacy in controlling the activity of the immune system and gives new hope for patients with autoimmune diseases and transplants. Part of Atlanpole Biotherapies cluster, the company was founded in December 2007 and grew out of from the Institute of Transplantation Urology Nephrology-(ITUN) Nantes.

Effimune

The expertise of the company covers all stages of development, starting from target characterization, discovery of new molecules, proof of concept, pilot production and clinical batches, the regulatory preclinical development and Phase I/II clinical trials.

For more information, see www.effimune.com

Contacts :

Effimune

Maryvonne Hiance, Chairman

Phone: +33 (0) 240 412 834

Mobile :+33 (0) 680 060 183

mhiance@effimune.com

www.effimune.com

Acorelis

Gilles Petitot

Phone: 33 (0) 145 83 13 84

Mobile : 33 (0) 620 27 65 94

gilles.petitot@acorelis.com